title: The current status of neoadjuvant therapy for esophageal cancer.
abstract: Through the contribution of a very large number of single-arm phase II trials and many less randomized phase III trials, the standard of care for locally advanced esophageal cancer has evolved to either combination chemotherapy plus radiation or combination chemotherapy. In this review, we focus on the key findings of these studies and selected meta-analyses that have led to this evolution. We note differences in outcomes for adenocarcinomas of the esophagus when compared to squamous cell esophageal cancers. Despite progress in developing a consensus for therapy, the outcome for patients with locally advanced remains poor. We complete the review by noting newer areas of investigation seeking to provide targeted and more personalized therapy to patients with esophageal cancer.
authors.affiliation: Department of Medicine, NYU School of Medicine, NYU Langone Medical Center, New York, New York; Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
authors.forename: Daniel
authors.initials: D
authors.lastname: Lin
authors.affiliation: Department of Medicine, NYU School of Medicine, NYU Langone Medical Center, New York, New York; Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York. Electronic address: Lawrence.Leichman@nyumc.org.
authors.forename: Lawrence
authors.initials: L
authors.lastname: Leichman
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant; D017024:Chemotherapy, Adjuvant; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000077277:Esophageal Squamous Cell Carcinoma; D006801:Humans; D058990:Molecular Targeted Therapy; D020360:Neoadjuvant Therapy / Q000009:adverse effects / Q000401:mortality; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
keywords: Esophagus cancer; neoadjuvant therapy